Method 1: Results

**Conclusions**

This first study designed to assess the risk of immunoresistance to BTX-B shows that BTX-B offers a useful alternative to patients with immunoresistance to BTX-A, but long-term efficacy is limited by the development of blocking Abs, probably as a result of cross-reactivity between the two serotypes.

**References**